Surrozen, Inc. (SRZN): Cash & Equivalents
$89.25M
As of 2025-12-31
$102.04M
As of 2026-06-30
+53.5%
3-year compound annual growth
+20.6%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $89.25M | +158.2% | 2026-03-23, Balance as of period end |
| 2024-12-31 | $34.56M | -4.1% | 2026-03-23, Balance as of period end |
| 2023-12-31 | $36.04M | +46.0% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $24.69M | -25.4% | 2024-04-10, Balance as of period end |
| 2021-12-31 | $33.09M | -5.4% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $34.98M | n/a | 2022-03-28, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Surrozen, Inc. (SRZN) | 2025-12-31 | $89.25M | +158.2% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $347.56M | +16.5% |
| Dyadic International Inc (DYAI) | 2025-12-31 | $4.62M | -29.0% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $32.49M | -87.4% |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $63.03M | -65.5% |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $18.30M | -50.5% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $194.17M | +498.2% |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $50.50M | +12.4% |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $46.63M | +29.3% |
Compare SRZN, CRSP, DYAI, CGON side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗